

University of Groningen

Role of VEGFA, CXCR4 and VHL mutation in tumour behaviour

Kruizinga, Roeliene

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2014

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Kruizinga, R. (2014). *Role of VEGFA, CXCR4 and VHL mutation in tumour behaviour*. [S.l.]: s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Role of VEGFA, CXCR4 and VHL mutation in tumour behaviour

Roeliene C. Kruizinga



Kruizinga, R.C.
Role of VEGFA, CXCR4 and VHL mutation in tumour behaviour
Thesis, University of Groningen, The Netherlands

ISBN (hardcopy): 978-90-367-6876-4
ISBN (electronic version): 978-90-367-6875-7

© Roeliene C. Kruizinga, Amsterdam, The Netherlands, 2013

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.

Cover design: R.C. Kruizinga, C.J.J. van Zeijl
Lay-out: www.persoonlijkproefschrift.nl
Printed by: Ipskamp Drukkers, Enschede, The Netherlands

Printing of this thesis was financially supported by: University of Groningen, Graduate School of Medical Sciences (UMCG), Stichting werkgroep Interne Oncologie, the Endocrinology Fund, as part of the Ubbo Emmius Fund.



rijksuniversiteit
 groningen

Role of VEGFA, CXCR4 and VHL mutation in tumour behaviour

Proefschrift

ter verkrijging van de graad van doctor aan de
 Rijksuniversiteit Groningen
 op gezag van de
 rector magnificus prof. dr. E. Sterken
 en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

maandag 28 april 2014 om 16.15 uur

door

Roeliene Catherien Kruizinga

geboren op 7 augustus 1986
 te Groningen

Promotores

Prof dr. T.P. Links

Prof dr. E.G.E. De Vries

Copromotor

Dr. A.M.E. Walenkamp

Beoordelingscommissie

Prof. dr. C.J.M. Lips

Prof. dr. H.M.W. Verheul

Prof. dr. E. Vellenga

Paranimfen:

Jennifer C. Boer

Nicolaas G.J. Schouten

CONTENTS

Chapter 1	General introduction	9
Chapter 2	Role of chemokines and their receptors in cancer <i>Curr Pharm Des 2009;15:3396-416.</i>	15
Chapter 3	A review on CXCR4/CXCL12 axis in oncology: no place to hide <i>Eur J Cancer 2013 Jan;49(1):219-30</i>	55
Chapter 4	Vascular endothelial growth factor A isoform mRNA expression in paediatric acute myeloid leukaemia <i>Pediatr Blood Cancer 2011;56:294-7</i>	77
Chapter 5	Overexpression of CXCR4, CXCL12 and VEGF-A in VHL-related and Sporadic Haemangioblastomas. <i>Submitted</i>	87
Chapter 6	Calculating optimal surveillance for detection of von Hippel-Lindau related manifestations <i>Endocrine Related Cancer 2013 oct 16 epub</i>	103
Chapter 7	Pregnancy-related haemangioblastoma progression and complications in von Hippel-Lindau disease <i>Neurology 2012 Aug 21;79(8):793-6.</i>	121
Chapter 8	Summary, Discussion and Future perspectives	131
Chapter 9	Nederlandse samenvatting	139
	Dankwoord	145
	Lijst van publicaties	147

